Archive for 2013

Why big pharma invests in some emerging markets and not in others

Why big pharma invests in some emerging markets and not in others

This was presented by AstraZeneca’s Executive Director & Head of External Collaborations for Emerging Markets, Ajay Gautam, at the Biopharma Mexico Convention held in Mexico City last October. AZ, along with other big pharma, have looked to emerging markets such as Brazil, China, Korea, Taiwan, Russia and Israel for innovation. What do these markets have that […]

Continue Reading

Video: John Duguid of Genzyme on rapid microbiological methods in cell therapy

Video: John Duguid of Genzyme on rapid microbiological methods in cell therapy

Written by on December 17, 2013 in Cell Culture, Featured Videos with 0 Comments

John Duguid, Principal Process/Analytical Scientist, Manufacturing Technical Services at Genzyme, speaks on ‘Rapid Microbiological Methods in autologous cell therapy: advantages, limitations, support and obstacles.’ If you liked this video then why not have a look at our other videos from Cell Culture World Congress USA 2013. Cell Culture World Congress USA is North America’s premier […]

Continue Reading

Download: A-Z of Clinical Trials

Download: A-Z of Clinical Trials

Written by on December 17, 2013 in Clinical Trials with 1 Comment

Clinical trials are currently undergoing a massive overhaul in how they are designed and executed. With the cost of clinical trials skyrocketing in the west, new innovations are providing researchers with the tools to improve data quality whilst reducing costs: Something that is especially important given drying up of the new substance pipelines across the […]

Continue Reading

Download: Interviews with leaders in the antibody sector – the future of R&D in the antibody, ADC and bispecific space

Download: Interviews with leaders in the antibody sector – the future of R&D in the antibody, ADC and bispecific space

Written by on December 16, 2013 in Antibodies, Drug Discovery, Manufacturing, Partnering & Investment with 0 Comments

There is undoubtedly a great deal of research going on within the antibody space, a significant number of therapeutics in the clinic and a lot of upcoming developments to watch out for. At the recent European Antibody Congress 2013, we took some time out to conduct some interviews with key members of the speaker faculty […]

Continue Reading

4 Ways Crowdsourcing Can Revolutionise Pharma Development: Part 4 Funding

4 Ways Crowdsourcing Can Revolutionise Pharma Development: Part 4 Funding

Continue Reading

Inforgraphic: Innovation in Pharma 2013

Inforgraphic: Innovation in Pharma 2013

Written by on December 12, 2013 in Drug Discovery, Partnering & Investment with 3 Comments

Last week saw Deloitte publish it’s fourth annual report looking at the return on investment pharmaceutical companies are seeing in their research and development projects. The report, co-produced with Thomson Reuters, looks at the current state of development pipelines in 12 top life science companies, and calculates a projected financial return for their products in […]

Continue Reading

Innovation in Pharma 2013: Top tips for the future

Innovation in Pharma 2013: Top tips for the future

Written by on December 12, 2013 in Clinical Trials, Drug Discovery with 1 Comment

Last week saw Deloitte publish it’s fourth annual report looking at the return on investment pharmaceutical companies are seeing in their research and development projects. The report, co-produced with Thomson Reuters, looks at the current state of development pipelines in 12 top life science companies, and calculates a projected financial return for their products in […]

Continue Reading

Guest Blog: Thoughts on the antibody sector

Guest Blog: Thoughts on the antibody sector

Written by on December 12, 2013 in Antibodies, Manufacturing with 0 Comments

The thoughts below were contributed by one of the Guest Bloggers at the European Antibody Congress, held in November 2013. Read on for a wrap-up of this event, and to see this blogger's thoughts on the antibody sector at present, and where new and exciting developments could take place in years to come.   From […]

Continue Reading

New Report Seeks to Quantify the Impact of Digital Marketing for Pharma

New Report Seeks to Quantify the Impact of Digital Marketing for Pharma

Written by on December 11, 2013 in Engagement & Communications with 1 Comment

We here at Total Biopharma have always been positive about the role social media can play in the pharma industry, and we certainly aren’t alone. But there has so far been little investigation into the effects of social media marketing for pharma companies, or the possibilities it can hold. But this hasn’t stopped pharma companies […]

Continue Reading

Top 50 Pharmaceutical Companies by R&D in 2013

Top 50 Pharmaceutical Companies by R&D in 2013

Written by on December 10, 2013 in Drug Discovery, Engagement & Communications, Featured on app with 1 Comment

The Pharmaceutical and Biotechnology industries continues to dominate the world’s R&D expenditure according to the 2013 EU Industrial R&D Scoreboard. Whilst the top 5 spots may be taken up by automobile, electronics, and software companies, it is pharmaceutical companies who dominate the second half of the top 10. With the top five companies spending accounting […]

Continue Reading

Top
Geolocation